Different Infection Risks for MS Treatments

Share this post

New study results suggest rituximab has a higher risk of serious infections than fingolimod or natalizumab, but a lower risk of herpetic infections.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply